Otonomy (OTIC) Receiving Favorable Media Coverage, Analysis Finds
Press coverage about Otonomy (NASDAQ:OTIC) has been trending positive this week, Accern Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Otonomy earned a news sentiment score of 0.26 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 44.4096619842869 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:
- Otonomy, Inc. :OTIC-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 (finance.yahoo.com)
- Otonomy, Inc. (OTIC) Receives Outperform Rating from Cowen and Company (americanbankingnews.com)
- Otonomy, Inc. – Value Analysis (NASDAQ:OTIC) : August 21, 2017 (finance.yahoo.com)
- Otonomy, Inc. (NASDAQ:OTIC) Sees Unusual Trading Volume in Its Shares (highlightpress.com)
- Implied Volatility Surging for Otonomy, Inc. (OTIC) Stock Options (finance.yahoo.com)
Shares of Otonomy (NASDAQ OTIC) opened at 20.50 on Friday. Otonomy has a 12-month low of $11.30 and a 12-month high of $20.75. The firm has a 50 day moving average price of $18.74 and a 200 day moving average price of $15.26. The stock’s market cap is $621.21 million.
Otonomy (NASDAQ:OTIC) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.80) by $0.03. The firm had revenue of $0.33 million for the quarter, compared to analyst estimates of $0.43 million. Otonomy had a negative net margin of 8,172.38% and a negative return on equity of 57.43%. Otonomy’s quarterly revenue was up 312.5% compared to the same quarter last year. During the same period last year, the company posted ($0.98) EPS. On average, equities analysts expect that Otonomy will post ($3.36) EPS for the current year.
A number of analysts recently issued reports on the company. Piper Jaffray Companies reissued an “overweight” rating and set a $32.00 price objective on shares of Otonomy in a report on Friday, June 30th. Zacks Investment Research raised Otonomy from a “sell” rating to a “hold” rating in a report on Tuesday, July 18th. Cowen and Company reissued an “outperform” rating and set a $55.00 price objective on shares of Otonomy in a report on Wednesday. J P Morgan Chase & Co raised Otonomy from a “neutral” rating to an “overweight” rating and set a $28.00 price objective on the stock in a report on Tuesday, August 15th. Finally, BidaskClub cut Otonomy from a “buy” rating to a “hold” rating in a report on Friday, August 11th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $32.50.
WARNING: “Otonomy (OTIC) Receiving Favorable Media Coverage, Analysis Finds” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.thecerbatgem.com/2017/08/25/otonomy-otic-receiving-favorable-media-coverage-analysis-finds.html.
In related news, insider Eric J. Loumeau sold 3,522 shares of the firm’s stock in a transaction dated Monday, June 26th. The shares were sold at an average price of $18.59, for a total value of $65,473.98. The sale was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 12.70% of the company’s stock.
Otonomy, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company’s product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase.
Receive News & Stock Ratings for Otonomy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy Inc. and related stocks with our FREE daily email newsletter.